Home | Welcome to Contract Pharma   
Last Updated Tuesday, September 30 2014
Print

Financial Report: PAREXEL



Published August 7, 2014
PAREXEL

4Q Revenues: $585.1 million (+11%)

4Q Earnings: $40.1 million (+34%)

FY Revenues: $2.3 billion (+14%)

FY Earnings: $129.1 million (+34%)

Comments: Consolidated service revenue increased 10% in the quarter to $510.6 million, with $385.6 million in Clinical Research Services (CRS), $55.2 million in PAREXEL Consulting (PC), and $69.8 million in PAREXEL Informatics (PI). For the year consolidated service revenue was up 12% to $1.9 billion, with $1.5 billion in CRS, $216.2 million in PC, and $267.9 million in PAREXEL Informatics, Inc.The recent acquisition of the HERON Group contributed approximately $3.8 million in the quarter, and contributed $2.2 million for the fiscal year. Backlog at the end of June 2014 was $5.0 billion, up 9% for the year.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On